Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases

Author:

Hadzidimitriou Anastasia1,Agathangelidis Andreas123,Darzentas Nikos1,Murray Fiona4,Delfau-Larue Marie-Helene56,Pedersen Lone Bredo7,Lopez Alba Navarro8,Dagklis Antonis9,Rombout Paul10,Beldjord Kheira11,Kolstad Arne12,Dreyling Martin H.13,Anagnostopoulos Achilles2,Tsaftaris Athanasios1,Mavragani-Tsipidou Penelope3,Rosenwald Andreas14,Ponzoni Maurilio15,Groenen Patricia10,Ghia Paolo9,Sander Birgitta16,Papadaki Theodora17,Campo Elias8,Geisler Christian7,Rosenquist Richard4,Davi Frederic18,Pott Christiane19,Stamatopoulos Kostas12

Affiliation:

1. Institute of Agrobiotechnology, Center for Research and Technology Hellas, Thessaloniki, Greece;

2. Department of Hematology and Hematopoietic Cell Transplantation (HCT) Unit, G. Papanicolaou Hospital, Thessaloniki, Greece;

3. School of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece;

4. Department of Immunology, Genetics, and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden;

5. Hopital Henri Mondor, Assistance Publique–Hôpitaux de Paris (AP-HP), and Universite Paris–XII Val de Marnes, Creteil, France;

6. Department of Immunology, Hopital Henri Mondor AP-HP, and Universite Paris–XII Val de Marne, Creteil, France;

7. Department of Haematology, Rigshospitalet, Copenhagen, Denmark;

8. Department of Pathology, Hospital Clinic, and Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain;

9. Laboratory of B Cell Neoplasia and Unit of Lymphoid Malignancies, Università Vita-Salute San Raffaele and Istituto Scientifico San Raffaele, Milan, Italy;

10. Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands;

11. Hôpital Necker AP-HP, Paris, France;

12. Department of Oncology, The Norwegian Radium Hospital, Oslo, Norway;

13. Department of Internal Medicine III, University Hospital Munich–Campus Grosshadern, Munich, Germany;

14. Pathology Department, University of Wuerzburg, Wuerzburg, Germany;

15. Pathology Unit and Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan, Italy;

16. Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet and Karolinska University Hospital, Huddinge, Sweden;

17. Department of Hematopathology, Evangelismos Hospital, Athens, Greece;

18. Service d'Hematologie Biologique, AP-HP, Hopital Pitié-Salpêtrière, Paris, France; and

19. Second Department of Medicine, University Medical Center Schleswig-Holstein, Kiel, Germany

Abstract

Abstract We examined 807 productive IGHV-IGHD-IGHJ gene rearrangements from mantle cell lymphoma (MCL) cases, by far the largest series to date. The IGHV gene repertoire was remarkably biased, with IGHV3-21, IGHV4-34, IGHV1-8, and IGHV3-23 accounting for 46.3% of the cohort. Eighty-four of 807 (10.4%) cases, mainly using the IGHV3-21 and IGHV4-34 genes, were found to bear stereotyped heavy complementarity-determining region 3 (VH CDR3) sequences and were placed in 38 clusters. Notably, the MCL stereotypes were distinct from those reported for chronic lymphocytic leukemia. Based on somatic hypermutation (SHM) status, 238/807 sequences (29.5%) carried IGHV genes with 100% germ line identity; the remainder (569/807; 70.5%) exhibited different SHM impact, ranging from minimal (in most cases) to pronounced. Shared replacement mutations across the IGHV gene were identified for certain subgroups, especially those using IGHV3-21, IGHV1-8, and IGHV3-23. Comparison with other entities, in particular CLL, revealed that several of these mutations were “MCL-biased.” In conclusion, MCL is characterized by a highly restricted immunoglobulin gene repertoire with stereotyped VH CDR3s and very precise SHM targeting, strongly implying a role for antigen-driven selection of the clonogenic progenitors. Hence, an antigen-driven origin of MCL could be envisaged, at least for subsets of cases.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference47 articles.

1. Current treatment standards and emerging strategies in mantle cell lymphoma.;Dreyling;Hematology Am Soc Hematol Educ Program,2009

2. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.;Pérez-Galán;Blood,2011

3. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma.;Espinet;Genes Chromosomes Cancer,2010

4. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.;Jares;Nat Rev Cancer,2007

5. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling.;Hartmann;Blood,2010

Cited by 145 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3